Clinical Trials Browser

Phase 1/2 × Craniopharyngioma × anlotinib × Clear all

NCT06970145 2025-11-18

Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

Phase 1/2 Recruiting

Craniopharyngioma